- Strong result improvement with 6% EBITDA margin in Q2 2020
Ras Al Khaimah (UAE) – Gulf Pharmaceutical Industries PSC (Julphar), one of the largest pharmaceutical manufacturers in the Middle East and Africa, has reported its financial results for the second quarter of 2020.
As of June 2020, the company generated AED 169.7 million in sales representing a 90% increase in comparison to Q2 2019, owing to the lift of the temporary suspension on export of products to Kuwait, Saudi Arabia, Oman and Bahrain earlier this year and growth in several of its core markets. In addition, Julphar has announced a net loss of AED 25.6 million which is an improvement of 73% versus Q2 2019, achieved due to the increase in net sales, expense reduction and gross margin improvement.
In July, Julphar successfully restructured its capital base following the completion of the rights issue which was oversubscribed by 2.3 times indicating strong investor confidence.
His Highness Sheikh Saqer Humaid Al Qasimi, Chairman of the Board, Julphar, said: “It is deeply encouraging to witness the improvement in sales and reduction of losses over the last quarter, which is testament to the resilience of the company’s business model and exemplary vision. The progress we have achieved is instrumental to sustain our 40-year legacy of providing advanced healthcare solutions globally.”
Dr. Essam Farouk, Chief Executive Officer of Julphar, said: “Following the successful capital restructuring and the return to Saudi Arabia and all GCC markets, we are progressing on plan towards achieving profitability and to further enhance our business performance. By maintaining the course in our transformation, we continue our mission to offer full disease management to the millions of people that we proudly serve locally, regionally, and globally.”
In 2020, Julphar announced the relaunch of over 80 products in Saudi Arabia, Kuwait, Bahrain, and Oman after the confirmation of its full compliance with Good Manufacturing Practices (GMP) through an inspection conducted by the Gulf Health Council (GHC) and the Saudi Food and Drug Authority (SFDA). The company has also made strategic senior C-suite appointments to deliver a greater impact in the 50 markets that Julphar operates in.
The future plans of Julphar focus on the strategic areas of the business as the company divests from non-core subsidiaries, regains market position in Saudi Arabia, Kuwait and Oman, continues to build new alliances and partnerships to strengthen the company’s product portfolio, launch new products in core therapeutic areas and invest in capital expenditure to improve operations efficiency.
-Ends-
About Julphar
Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa, and for four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 3,500 people and distributes pharmaceutical products to more than 50 countries on five continents.
Julphar’s business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastroenterology, Pain Management, Wound Care, Antibiotics and Cardio-Metabolism. Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia. In 2012, Julphar became one of the largest producers of Insulin with its UAE-based biotechnology production unit.
For more information, visit http://www.julphar.net
Media contact:
Wael Al Kubbani,
Account Executive,
Hill+Knowlton Strategies
Wael.AlKubbani@hkstrategies.com
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
